Encouraging results from the Phase I combination study with Oncoral and oral capecitabine published in the journal Cancer Chemotherapy and Pharmacology
Ascelia Pharma AB (ticker: ACE), announces results from the Phase I investigator-sponsored extension study (ClinicalTrials.gov Identifier: NCT03295084) demonstrating reassuring tolerability of the oral chemotherapy tablet Oncoral (oral irinotecan) administered in combination with oral capecitabine. These results are published in Cancer Chemotherapy and Pharmacology, a peer reviewed medical journal covering oncological pharmacotherapy.The Phase I study for Oncoral consisted of two parts. The first, where Oncoral was given as a single agent, was published last fall showing promising results.
